Candel Publishes Final Phase Of 2a Clinical Trial Results Of of Aglatimagene Besadenovec Plus Valacyclovir In Patients With Stage III/IV NSCLC Showing Inadequate Response To ICI.

Peer-reviewed publication in Journal for ImmunoTherapy of Cancer reports median overall survival of 24.5 months in advanced non-small cell lung cancer (NSCLC) patients with inadequate response to immune checkpoint inhibitors (ICI)